PNP20: ANTIPSYCHOTIC UTILIZATION RATIOS: DIFFERENCES AMONG AGE, GENDER, AND PAYER COMBINATIONS  by Hutchins, D et al.
176 Abstracts
the elderly in 1996. This represents 8.7% of all clinic vis-
its by the elderly for an annual visit rate of 51.97 (visits
for every 100 persons of 65 years old or older). Ninety-
one percent of these visits were to physician offices and
remaining visits were to outpatient clinics. There were
some variations in psychotropic prescribing patterns be-
tween these two settings. Overall, psychotropic medica-
tion visit rates were greater in females, blacks, patients
between 80 and 84 years of age, and patients from the
West. The most frequently prescribed psychotropic medi-
cations in ambulatory clinics in the order of prevalence
were antidepressants, antianxiety agents, and sedatives.
Most of the visits (81.67%) involved one psychotropic
medication and 3.14% of the visits involved two or more
agents in the same class.
CONCLUSION: The study revealed that psychotropic
prescribing practices in ambulatory clinics vary with eld-
erly demographics and clinical settings. Because of the in-
creased risk related to the use of psychotropics and the
prescribing patterns of these agents, future efforts may be
focused on populations receiving relatively more psycho-
tropic agents to improve healthcare outcomes.
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Burden-of-illness assessments require incidence and prev-
alence assumptions. For psychotic disorders, there are
few large-scale incidence and prevalence assessments pro-
viding rates for age, gender, or socioeconomic subpopu-
lations. Because outpatient treatment of psychotic condi-
tions is increasing, overall incidence and prevalence may
be estimated from outpatient pharmaceutical records.
OBJECTIVE: This study estimates incidence and prevalence
of antipsychotic utilization among age, gender, and payer
combinations using outpatient pharmaceutical records.
METHODS: Antipsychotic prescriptions dispensed be-
tween July 1995 and June 1997 to 4,628,528 eligible
subjects were extracted from a large US database. Calcu-
lated ratios compared utilizers (eligible subjects with a
prescription between July 1996 and June 1997) and initi-
ators (utilizers without a prescription between July 1995
and June 1996) to eligible subjects for various combina-
tions of age, gender, and payer types—Medicaid, non-
Medicaid, indemnity, or “self-insured.” Chi-square tests
were used to assess differences between those receiving
and not receiving antipsychotic agents.
RESULTS: The utilizer ratio was 5.0 per 1000, although
significantly (p  0.002) lower (by 1.1 per 1000) for
males. The initiator ratio was 1.6 per 1000, again signifi-
cantly (p  0.001) lower (by 0.1 per 1000) for males.
Differences were not consistent—higher for younger
males and lower for older males than for similarly aged
females. Ratios were significantly (p 	 0.001) higher (by
10 times) for Medicaid recipients.
CONCLUSION: Outpatient ratios were within overall
prevalence and incidence rates for schizophrenia or other
psychotic conditions. Integrating these ratios into a bur-
den-of-illness analysis should consider the proportions of
non-psychotic disorders, patients treated for psychotic
conditions without medication, and patients treated solely
on an inpatient basis.
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Heroin is an extremely devastating drug. Injection of her-
oin is a major risk factor for infectious diseases such as
HIV/AIDS and hepatitis. Heroin addiction often strikes
persons in the prime of their working years, robbing soci-
ety of productive citizens. Furthermore, a significant pro-
portion of heroin users engages in criminal activities to
support their habit.
OBJECTIVE: This study documents the tremendous
costs of heroin addiction, both to the addict and society
at large.
METHODS: Using a cost-of-illness approach, we identify
costs in three major areas: 1) medical care, 2) productivity,
and 3) crime. No single data set currently available is able
to fully capture costs in each of these areas. Thus, a variety
of data sets and previous studies have been synthesized.
RESULTS: We estimate that in 1996 the economic costs
of heroin addiction in the United States totaled $22.1 bil-
lion. Approximately 23% of these costs are due to the
medical complications of heroin addiction, primarily
treatment for HIV/AIDS and psychiatric comorbidities.
Another 24% are related to criminal activities, including
the cost of incarceration, policing, legal adjudication, and
the cost to crime victims. Another 41% are associated
with lost productivity. For example, heroin addicts are
less than half as likely to have a full-time job as com-
pared with the national average. Treatment of heroin ad-
diction and social welfare services each account for 5%
of the costs.
CONCLUSIONS: The significant economic effects of
heroin addiction have important public policy implica-
tions, especially given that heroin use appears to be rising
among adolescents and young adults. This study suggests
that greater investment in prevention and treatment ac-
tivities may be highly cost-effective.
PNP22
HYPNOTIC DRUGS CONSUMPTION IN RUSSIA
Gorkov V, Kobina S, Chapurin Y, Churilin S
Center of Mental Health, Moscow, Russia
